HT
FDMT icon

Headlands Technologies’s 4D Molecular Therapeutics FDMT Stock Holding History

Headlands Technologies’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Buy
19,238
+3,282
+21% +$32K 0.03% 563
2026
Q1 		$149K Buy
+15,956
New +$139K 0.02% 635

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Headlands Technologies's FDMT Position: Q2 2026 in Review

Headlands Technologies increased its 4D Molecular Therapeutics (FDMT) stake by 21% in Q2 2026, buying an estimated $32K and bringing the position to 19,238 shares worth $256K. The position accounts for 0.03% of the portfolio, ranked #563.

Headlands Technologies first reported a position in FDMT in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Headlands Technologies held 19,238 shares of 4D Molecular Therapeutics worth $256K as of Q2 2026.
  • Headlands Technologies bought 3,282 4D Molecular Therapeutics shares in Q2 2026, an estimated $32K.
  • 4D Molecular Therapeutics made up 0.03% of Headlands Technologies's portfolio in Q2 2026, its #563 holding.
  • Headlands Technologies first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.